Technical Analysis for VTYX - Ventyx Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| 20 DMA Resistance | Bearish | 3.37% | |
| Crossed Above 50 DMA | Bullish | 3.37% | |
| 20 DMA Resistance | Bearish | 3.61% | |
| 50 DMA Resistance | Bearish | 3.61% | |
| MACD Bearish Signal Line Cross | Bearish | 3.61% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 3% | about 9 hours ago |
| Rose Above Previous Day's High | about 9 hours ago |
| Outside Day | about 9 hours ago |
| Up 2% | about 9 hours ago |
| Rose Above 20 DMA | about 9 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/03/2023
Ventyx Biosciences, Inc. Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Autoimmune Disease Inflammatory Diseases Psoriasis Inflammatory Bowel Disease Ulcerative Colitis Cytokine Autoimmune Disorders Lupus Psoriatic Arthritis Immune Mediated Diseases Molecule Product Inflammasome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 47.2508 |
| 52 Week Low | 23.8934 |
| Average Volume | 496,739 |
| 200-Day Moving Average | 35.70 |
| 50-Day Moving Average | 34.09 |
| 20-Day Moving Average | 34.65 |
| 10-Day Moving Average | 35.56 |
| Average True Range | 1.70 |
| RSI (14) | 53.92 |
| ADX | 14.89 |
| +DI | 20.34 |
| -DI | 16.53 |
| Chandelier Exit (Long, 3 ATRs) | 33.04 |
| Chandelier Exit (Short, 3 ATRs) | 36.94 |
| Upper Bollinger Bands | 37.51 |
| Lower Bollinger Band | 31.79 |
| Percent B (%b) | 0.61 |
| BandWidth | 16.50 |
| MACD Line | 0.38 |
| MACD Signal Line | 0.48 |
| MACD Histogram | -0.098 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 38.69 | ||||
| Resistance 3 (R3) | 38.38 | 36.92 | 38.12 | ||
| Resistance 2 (R2) | 36.92 | 36.05 | 37.08 | 37.93 | |
| Resistance 1 (R1) | 36.10 | 35.51 | 36.51 | 36.41 | 37.74 |
| Pivot Point | 34.64 | 34.64 | 34.85 | 34.80 | 34.64 |
| Support 1 (S1) | 33.82 | 33.77 | 34.23 | 34.13 | 32.80 |
| Support 2 (S2) | 32.36 | 33.23 | 32.52 | 32.61 | |
| Support 3 (S3) | 31.54 | 32.36 | 32.42 | ||
| Support 4 (S4) | 31.85 |
